Published in Proteomics Weekly, January 3rd, 2005
Sangamo is developing zinc finger DNA-binding proteins, or ZFPs, for therapeutic gene regulation and modification to treat conditions that include cardiovascular disease, diabetic neuropathy, pain, cancer monogenic diseases and HIV.
Companies selected as Technology Pioneers are developing and applying the most innovative and transformational technologies. This year's class of companies is at the forefront of work in fields such as nanotechnology, drug development, renewable energy and wireless technology. Their work has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.